Blocking CD38 Preserves Gut Lining During Chemotherapy by Restoring NAD+
A mouse study shows CD38 inhibition protects colon architecture during 5-FU chemotherapy by preventing NAD+ depletion.
Summary
Chemotherapy with 5-fluorouracil (5-FU) commonly damages the gut lining, causing painful mucositis. This study investigated whether the enzyme CD38 — a major consumer of NAD+ — drives this damage. Researchers gave mice 5-FU and then blocked CD38 with a small molecule called 78c. The treatment preserved the structural integrity of colon crypts, reduced inflammation and oxidative stress, lowered cell death signals, and restored the tight junctions that keep the gut barrier intact. These benefits depended entirely on NAD+ availability: when NAD+ production was separately blocked, the protective effects vanished. The findings position the CD38-NAD+ axis as a critical metabolic switch controlling gut resilience during chemotherapy, opening potential avenues for protecting cancer patients from treatment-related gut damage.
Detailed Summary
Chemotherapy-induced mucositis — damage to the gut lining — is one of the most debilitating side effects of cancer treatment, yet the precise metabolic pathways that drive or protect against this injury remain poorly understood. This study tackles a critical gap by examining how NAD+ metabolism, specifically the CD38 enzyme axis, governs the fate of colonic tissue during 5-fluorouracil (5-FU) chemotherapy.
Researchers used a well-established mouse model of 5-FU-induced colonic mucositis. They administered the small-molecule CD38 inhibitor 78c alongside 5-FU, then assessed histological, biochemical, and molecular markers of tissue damage. A separate group also received a NAMPT inhibitor to block NAD+ biosynthesis, testing whether the protective effects of CD38 inhibition truly depended on restoring NAD+ levels.
5-FU produced extensive colonic injury: epithelial cell death, crypt disorganization, inflammatory infiltration, oxidative damage, and breakdown of tight junction proteins that maintain the gut barrier. CD38 inhibition dramatically reversed these changes, preserving crypt architecture, reducing inflammation and apoptosis, restoring oxidative balance, and repairing the gut barrier. Mechanistically, protection correlated with higher colonic NAD+ levels, improved NAD+/NADH ratio, increased SIRT1 deacetylase activity, reduced PARP activation, and upregulation of the Nrf2 antioxidant pathway.
Critically, blocking NAD+ biosynthesis with the NAMPT inhibitor abolished all protective effects of CD38 inhibition, confirming that NAD+ replenishment — not some off-target effect of 78c — is the operative mechanism. This elegant rescue-and-ablation design strengthens the mechanistic conclusion considerably.
The implications are clinically meaningful. CD38 inhibitors are already in clinical use for multiple myeloma (e.g., daratumumab), and NAD+ precursor supplements are widely studied. This work raises the possibility that combining CD38 inhibition or NAD+ support with chemotherapy could reduce gut toxicity. Limitations include the preclinical mouse-only design and abstract-only availability for full methodological scrutiny.
Key Findings
- CD38 inhibition with compound 78c preserved colon crypt architecture and epithelial continuity in 5-FU-treated mice.
- Protection required NAD+ availability — blocking NAD+ biosynthesis completely abolished the benefits of CD38 inhibition.
- CD38 inhibition restored tight junction integrity and intestinal barrier function disrupted by 5-FU.
- Mechanistic benefits included elevated SIRT1 activity, reduced PARP activation, and Nrf2 antioxidant pathway upregulation.
- Oxidative stress, inflammatory infiltration, and apoptotic signaling were all significantly attenuated by CD38 inhibition.
Methodology
Mouse model of 5-FU-induced colonic mucositis treated with the CD38 inhibitor 78c. Outcomes included histopathology, biochemical markers of oxidative stress and inflammation, and molecular readouts including SIRT1, PARP, Nrf2, and tight junction proteins. A NAMPT inhibitor was used to confirm NAD+-dependence of the protective effects.
Study Limitations
This is a preclinical mouse study and results may not translate directly to human patients undergoing chemotherapy. The full methodology, dosing details, and statistical data are unavailable as this summary is based on the abstract only. Long-term safety of CD38 inhibition in the context of active cancer treatment has not been addressed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: